Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | PLAT | P00750 | 2/20 | 0.39 |
| ▸ | CTSH | P09668 | 2/20 | 0.39 |
| ▸ | CASP14 | P31944 | 2/20 | 0.39 |
| ▸ | CASP6 | P55212 | 2/20 | 0.39 |
| ▸ | CTSZ | Q9UBR2 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP5 | P51878 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416389 | 0.90 | ACHE (0.43) | PDE4AMAPK1NSD2CTSKCTSS | |
| Pyridine SCHEMBL4898097 | 0.87 | ACHE (0.40) | PDE4AMAPK1CTSKCTSSCTSL | |
| SCHEMBL9640912 | 0.84 | KMT2A (0.45) | PDE4AMAPK1NSD2CTSKCTSS | |
| SCHEMBL11165353 | 0.82 | MAPK8 (0.39) | PDE4AMAPK1NSD2CTSKCTSS | |
| SCHEMBL4899212 | 0.81 | KDM1A (0.47) | CTSKCTSSCTSLCTSVPLAT | |
| SCHEMBL4413397 | 0.80 | KDM4E (0.41) | PDE4AACHEKDM4E | |
| SCHEMBL4907005 | 0.79 | ACHE (0.41) | CTSKCTSSCTSLCTSVPLAT | |
| SCHEMBL4906201 | 0.79 | KMT2A (0.55) | ACHE | |
| SCHEMBL4906676 | 0.78 | ACHE (0.43) | CTSKCTSSCTSLCTSVPLAT | |
| SCHEMBL120066 | 0.77 | CTSK (0.38) | PDE4ACTSKCTSSCTSLCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | PDE4A 1/4885MAPK1 332/4885NSD2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.